PRTA - プロセナ (Prothena Corporation plc)

PRTAのニュース

   Recap: Prothena Corp Q2 Earnings  2022/08/08 21:07:14 Benzinga
Prothena Corp (NASDAQ: PRTA ) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Prothena Corp missed estimated earnings by 69.23%, reporting an EPS of $-0.88 versus … Full story available on Benzinga.com
   Prothena GAAP EPS of -$0.88 misses by $0.31 (NASDAQ:PRTA)  2022/08/08 20:54:04 Seeking Alpha
Prothena press release (PRTA): Q2 GAAP EPS of -$0.88 misses by $0.31.Collaboration revenue of $1.31M. As of June 30, 2022, Prothena had $510.1 million in cash, cash equivalents…
   Prothena Corporation plc: Prothena Reports Second Quarter 2022 Financial Results and Business Highlights  2022/08/08 20:17:00 Finanz Nachrichten
Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $51…
   Prothena Reports Second Quarter 2022 Financial Results and Business Highlights  2022/08/08 20:05:00 Finanzen CH
Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $510.1 million Broad Alzheimer’s disease portfolio…
   Prothena Q2 2022 Earnings Preview (NASDAQ:PRTA)  2022/08/05 21:35:31 Seeking Alpha
Prothena (PRTA) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close.The consensus EPS Estimate is -$0.53 and the consensus Revenue Estimate is…
   Why RBC Capital Sees ''Multiple High-Risk'' On This Neurology-Focused Stock  2022/05/02 19:44:04 Benzinga
RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA ) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the space could drive appreciation. Over the past month, the stock has lost 27%, and over the last six months, the stock price has dropped almost 50%. RBC lowered the price target from $82 to $45 following coverage transfer, maintaining Outperform, Speculative Risk rating. RBC sees … Full story available on Benzinga.com
   Prothena to Report First Quarter 2022 Financial Results on May 5th  2022/04/28 20:05:00 GlobeNewswire
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the close of the U.S. financial markets.
   Prothena Receives FDA Fast Track Designation for PRX012 for the Treatment of Alzheimer''s Disease  2022/04/26 13:34:53 Benzinga
Prothena Corporation plc (NASDAQ: PRTA ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-amyloid beta (Aβ) antibody therapy drug candidate PRX012 for the treatment of Alzheimer''s disease. PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy from Prothena, currently in a Phase 1 clinical … Full story available on Benzinga.com
   Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease  2022/04/26 12:30:00 GlobeNewswire
DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody therapy currently being investigated in a Phase 1 clinical study for the treatment of Alzheimer’s disease. The FDA’s Fast Track designation program is designed to expedite the development and review of drugs intended to treat a serious condition, such as Alzheimer’s disease, with evidence demonstrating the potential to address an unmet medical need.
   Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer''s Disease  2022/04/26 12:30:00 Benzinga
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer''s disease DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody therapy currently being investigated in a Phase 1 clinical study for the treatment of Alzheimer''s disease. The FDA''s Fast Track designation program is designed to expedite the development and review of drugs intended to treat a serious condition, such as Alzheimer''s disease, with evidence demonstrating the potential to address an unmet medical need. "We welcome the FDA''s decision to grant PRX012 Fast Track designation, which is designed to bring important new drugs to patients sooner, and we look forward to collaborating with the FDA to expedite the development of this investigational next-generation amyloid beta-targeting therapy for the millions of patients with Alzheimer''s disease and their families," said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. "We are pleased the FDA has recognized the evidence demonstrating the potential for PRX012 to address an unmet need in the treatment of Alzheimer''s disease.
   Prothena Corporation plc: Prothena to Participate in JMP Securities Hematology and Oncology Summit  2021/11/29 21:17:00 FinanzNachrichten
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o
   Prothena to Participate in JMP Securities Hematology and Oncology Summit  2021/11/29 21:05:00 Intrado Digital Media
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday December 6, 2021 at 1:20 PM ET.
   -$0.71 Earnings Per Share Expected for Prothena Co. plc (NASDAQ:PRTA) This Quarter  2021/11/27 21:06:41 Dakota Financial News
Wall Street brokerages forecast that Prothena Co. plc (NASDAQ:PRTA) will report earnings per share of ($0.71) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Prothenas earnings. The lowest EPS estimate is ($0.84) and the highest is ($0.52). Prothena reported earnings of ($0.77) per share in the same quarter last []
   Karin L. Walker Sells 4,519 Shares of Prothena Co. plc (NASDAQ:PRTA) Stock  2021/11/27 13:06:45 Dakota Financial News
Prothena Co. plc (NASDAQ:PRTA) CAO Karin L. Walker sold 4,519 shares of the companys stock in a transaction that occurred on Tuesday, November 23rd. The shares were sold at an average price of $57.88, for a total value of $261,559.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is []
   AQR Capital Management LLC Takes Position in Prothena Co. plc (NASDAQ:PRTA)  2021/11/23 11:34:41 Transcript Daily
AQR Capital Management LLC purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,917 shares of the biotechnology companys stock, valued at approximately $253,000. A number of other large investors have also modified []

calendar